Deciphera Pharmaceuticals Inc.

NAS: DCPH

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Deciphera Pharmaceuticals Inc.

After Hours

--Quotes are delayed by 20 min

Feb 3, 2023, 5:41 p.m.

DCPH

/zigman2/quotes/203556943/composite

17.00

Change

-0.03 -0.18%

Volume

Volume 15,717

Quotes are delayed by 20 min

/zigman2/quotes/203556943/composite

Previous close

$ 17.55

$ 17.03

Change

-0.52 -2.96%

Day low

Day high

$17.00

$17.65

52 week low

52 week high

$6.51

$22.76

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Deciphera Pharmaceuticals Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2017	2018	2019	2020	2021	5-year trend
Sales/Revenue	-	-	25M	42.09M	96.15M
Sales Growth	-	-	-	68.35%	128.45%
Cost of Goods Sold (COGS) incl. D&A	150,000	317,000	-	5.36M	9.39M
COGS excluding D&A	-	-	-	225,000	2.93M
Depreciation & Amortization Expense	150,000	317,000	830,000	5.14M	6.46M
Depreciation	150,000	317,000	830,000	5.14M	6.46M
Amortization of Intangibles	-	-	-	-	-
COGS Growth	-	111.33%	-	-	75.09%
Gross Income	(150,000)	(317,000)	24.17M	36.72M	86.76M
Gross Income Growth	-	-111.33%	7,724.61%	51.94%	136.24%
Gross Profit Margin	-	-	-	-	90.23%	NA

	2017	2018	2019	2020	2021	5-year trend
SG&A Expense	50.79M	103.78M	224.9M	307.91M	360.63M
Research & Development	39.51M	82.89M	156.78M	196.67M	231.83M
Other SG&A	11.27M	20.9M	68.12M	111.25M	-
SGA Growth	-	104.36%	116.70%	36.91%	17.12%
Other Operating Expense	-	-	-	-	-
Unusual Expense	-	-	-	-	26.2M
EBIT after Unusual Expense	-	-	-	-	(300.08M)
Non Operating Income/Expense	746,000	4.33M	8.54M	4.7M	113,000
Non-Operating Interest Income	-	-	-	-	-
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	95,000	84,000	67,000	-	-
Interest Expense Growth	-	-11.58%	-20.24%	-	-
Gross Interest Expense	95,000	84,000	67,000	-	-
Interest Capitalized	-	-	-	-	-
Pretax Income	(50.28M)	(99.85M)	(192.26M)	(266.49M)	(299.96M)
Pretax Income Growth	-	-98.58%	-92.54%	-38.61%	-12.56%
Pretax Margin	-	-	-	-	-311.98%	NA
Income Tax	-	-	-	-	-
Income Tax - Current Domestic	-	-	-	-	-
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	-	-	-	-	-
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(50.28M)	(99.85M)	(192.26M)	(266.49M)	(299.96M)
Minority Interest Expense	-	-	-	-	-
Net Income	(50.28M)	(99.85M)	(192.26M)	(266.49M)	(299.96M)
Net Income Growth	-	-98.58%	-92.54%	-38.61%	-12.56%
Net Margin Growth	-	-	-	-	-311.98%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(50.28M)	(99.85M)	(192.26M)	(266.49M)	(299.96M)
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(50.28M)	(99.85M)	(192.26M)	(266.49M)	(299.96M)
EPS (Basic)	(2.99)	(2.82)	(4.48)	(4.78)	(5.16)
EPS (Basic) Growth	-	5.64%	-58.95%	-6.53%	-8.10%
Basic Shares Outstanding	16.79M	35.39M	42.87M	55.78M	58.08M
EPS (Diluted)	(2.99)	(2.82)	(4.48)	(4.78)	(5.16)
EPS (Diluted) Growth	-	5.64%	-58.95%	-6.53%	-8.10%
Diluted Shares Outstanding	16.79M	35.39M	42.87M	55.78M	58.08M
EBITDA	(50.79M)	(103.78M)	(199.9M)	(266.05M)	(267.42M)
EBITDA Growth	-	-104.36%	-92.61%	-33.09%	-0.51%
EBITDA Margin	-	-	-	-	-278.13%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Deciphera Pharmaceuticals Inc.

Annual Financials for Deciphera Pharmaceuticals Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk